International Journal of Nanomedicine,
Год журнала:
2021,
Номер
Volume 16, С. 3937 - 3999
Опубликована: Июнь 1, 2021
Abstract:
Surfactants,
whose
existence
has
been
recognized
as
early
2800
BC,
have
had
a
long
history
with
the
development
of
human
civilization.
With
rapid
nanotechnology
in
latter
half
20th
century,
breakthroughs
nanomedicine
and
food
using
nanoparticles
remarkable,
new
applications
developed.
The
technology
surfactant-coated
nanoparticles,
which
provides
functions
to
for
use
fields
nanotechnology,
is
attracting
lot
attention
basic
research
industry.
This
review
systematically
describes
these
“surfactant-coated
nanoparticles”
through
various
sections
order:
1)
surfactants,
2)
application
3)
nanomedicine,
4)
nanotechnology.
Furthermore,
current
progress
problems
recent
reports
discussed.
Keywords:
drug
delivery
system,
targeting,
science,
packaging,
nonionic
safety
assessment
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Фев. 5, 2024
Abstract
Extracellular
vesicles
(EVs)
are
nano-sized,
membranous
structures
secreted
into
the
extracellular
space.
They
exhibit
diverse
sizes,
contents,
and
surface
markers
ubiquitously
released
from
cells
under
normal
pathological
conditions.
Human
serum
is
a
rich
source
of
these
EVs,
though
their
isolation
proteins
non-EV
lipid
particles
poses
challenges.
These
transport
various
cellular
components
such
as
proteins,
mRNAs,
miRNAs,
DNA,
lipids
across
distances,
influencing
numerous
physiological
events,
including
those
within
tumor
microenvironment
(TME).
Their
pivotal
roles
in
communication
make
EVs
promising
candidates
for
therapeutic
agents,
drug
delivery
systems,
disease
biomarkers.
Especially
cancer
diagnostics,
EV
detection
can
pave
way
early
identification
offers
potential
diagnostic
Moreover,
subtypes
emerging
targeted
tools,
highlighting
clinical
significance.
The
need
non-invasive
biomarkers
to
monitor
biological
processes
purposes
remains
unfulfilled.
Tapping
unique
composition
could
unlock
advanced
avenues
future.
In
this
review,
we
discuss
detail
conditions,
cancers
(encompassing
head
neck,
lung,
gastric,
breast,
hepatocellular
carcinoma),
neurodegenerative
disorders,
diabetes,
viral
infections,
autoimmune
renal
diseases,
emphasizing
advancements
molecular
diagnostics
delivery.
Drug Resistance Updates,
Год журнала:
2021,
Номер
59, С. 100796 - 100796
Опубликована: Дек. 1, 2021
Driver
mutations
promote
initiation
and
progression
of
cancer.
Pharmacological
treatment
can
inhibit
the
action
mutant
protein;
however,
drug
resistance
almost
invariably
emerges.
Multiple
studies
revealed
that
cancer
is
based
upon
a
plethora
distinct
mechanisms.
Drug
occur
in
same
protein
or
different
proteins;
as
well
pathway
parallel
pathways,
bypassing
intercepted
signaling.
The
dilemma
clinical
oncologist
facing
not
all
genomic
alterations
tumor
microenvironment
facilitate
cell
proliferation
are
known,
neither
likely
to
metastasis.
For
example,
common
KRas
Cancers,
Год журнала:
2021,
Номер
13(17), С. 4363 - 4363
Опубликована: Авг. 28, 2021
The
ability
of
tumor
cells
to
evade
apoptosis
is
established
as
one
the
hallmarks
cancer.
deregulation
apoptotic
pathways
conveys
a
survival
advantage
enabling
cancer
develop
multi-drug
resistance
(MDR),
complex
phenotype
referring
concurrent
toward
agents
with
different
function
and/or
structure.
Proteins
implicated
in
intrinsic
pathway
apoptosis,
including
Bcl-2
superfamily
and
Inhibitors
Apoptosis
(IAP)
family
members,
well
their
regulator,
suppressor
p53,
have
been
development
MDR
many
types.
PI3K/AKT
pivotal
promoting
proliferation
often
overactive
tumors.
In
addition,
microenvironment,
particularly
factors
secreted
by
cancer-associated
fibroblasts,
can
inhibit
reduce
effectiveness
anti-cancer
drugs.
this
review,
we
describe
main
alterations
that
occur
apoptosis-and
related
promote
MDR.
We
also
summarize
therapeutic
approaches
against
resistant
tumors,
targeting
small
molecule
inhibitors
IAPs
or
AKT
natural
origin
may
be
used
monotherapy
combination
conventional
therapeutics.
Finally,
highlight
potential
exploitation
epigenetic
modifications
reverse
phenotype.
Medicinal Research Reviews,
Год журнала:
2020,
Номер
41(1), С. 525 - 555
Опубликована: Окт. 12, 2020
Abstract
Multidrug
resistance
(MDR)
remains
one
of
the
major
impediments
for
efficacious
cancer
chemotherapy.
Increased
efflux
multiple
chemotherapeutic
drugs
by
transmembrane
ATP‐binding
cassette
(ABC)
transporter
superfamily
is
considered
primary
causes
MDR,
in
which
role
P‐glycoprotein
(P‐gp/
ABCB1
)
has
been
most
well‐established.
The
clinical
co‐administration
P‐gp
drug
inhibitors,
combination
with
anticancer
are
transport
substrates,
was
to
be
a
treatment
modality
surmount
MDR
therapy
blocking
P‐gp‐mediated
multidrug
efflux.
Extensive
attempts
have
carried
out
screen
sets
nontoxic,
selective,
and
inhibitors.
In
this
review,
we
highlight
recent
achievements
design,
characterization,
structure–activity
relationship
(SAR)
studies,
mechanisms
action
newly
synthetic,
potent
small
molecules
inhibitors
past
5
years.
development
will
increase
our
knowledge
functions
benefit
discovery
therapeutics
where
overexpression
implicated
MDR.
